COMMUNIQUÉS West-GlobeNewswire

Idera Pharmaceuticals Reports Results from Phase 2 Trial of IMO-8400 in Dermatomyositis
12/06/2018
Clinical trial did not meet primary endpoint of statistically significant reduction of CDASI for IMO-8400 versus placebo EXTON, Pa., June 12, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a [...]
Avalon GloboCare Forms Joint Venture with Jiangsu Unicorn to Establish Provincial Network of Translational Cellular Therapy and Bio-Banking Programs
12/06/2018
FREEHOLD, N.J., June 12, 2018 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (OTCQB:AVCO), a leading global developer of cell-based technologies, announced today that the Company has formed a joint venture with Jiangsu [...]
Restoration Robotics Launches New Continuing Education Master Class Series for the ARTAS® Robotic Hair Restoration System
12/06/2018
First class in new continuing education series led by prominent aesthetic surgeon, Robert M. Bernstein, MD in New York, NY Additional Master Classes in the series to be led by experienced faculty SAN JOSE, Calif., June [...]
Phase 3 data in the online Journal of the American Academy of Dermatology show Aclaris' ESKATA™ is safe and effective in treating persons with raised seborrheic keratoses
12/06/2018
WAYNE, Pa., June 12, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to [...]
CureVac Announces Appointment of Matthew L. S. Beck as Vice President of Investor Relations
12/06/2018
TÜBINGEN, Germany and BOSTON, June 12, 2018 (GLOBE NEWSWIRE) -- CureVac AG, a fully-integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced the appointment of Matthew L. S. Beck as [...]
Surface Oncology Announces Initiation of Phase I Clinical Trial of SRF373 / NZV930
12/06/2018
CAMBRIDGE, Mass., June 12, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today [...]
Chimerix Announces Discovery and Demonstrated Preclinical Activity Supporting Ongoing Phase 1 Study of New Antiviral for Treatment and Prevention of Norovirus
12/06/2018
- CMX521 is Active In Vitro Against All Strains of Norovirus Tested - - Oral Dosing of CMX521 Inhibited Norovirus Replication in Animal Model - DURHAM, N.C., June 12, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a [...]
ProQR Receives up to $5 Million in Partnership with EB Research Partnership and EB Medical Research Foundation to Develop QR-313 for the Treatment of Dystrophic Epidermolysis Bullosa
12/06/2018
The funding will be used for the clinical development of QR-313 Clinical trial in DEB patients to start in the second quarter of 2018 LEIDEN, the Netherlands, June 12, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. ( [...]
Asterias Biotherapeutics Announces First Patient Dosed in First-in-Human Clinical Study of Immunotherapy AST-VAC2 in Non-Small Cell Lung Cancer
12/06/2018
FREMONT, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and cell-based therapeutics to [...]
Radient Technologies Inc. Files FDA Submission for Reducing Nicotine in Tobacco
12/06/2018
EDMONTON, Alberta, June 12, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture:RTI) is pleased to announce that it has made a submission to the U.S. Food and Drug Administration [...]
Pluristem Reports Positive Top-Line Results from Its Multinational Phase II Intermittent Claudication Study
12/06/2018
PLX-PAD treatment reduced risk of revascularization and improved patients’ mobility. Study validates the design of Pluristem’s ongoing Pivotal Phase III study in Critical Limb Ischemia (CLI) HAIFA, Israel, June 12, 2018 [...]
Transactions in relation to share buyback program
12/06/2018
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
Amarin and Mochida Announce Collaboration on Future Development of EPA-based Drug Products and Indications
12/06/2018
BEDMINSTER, N.J. and DUBLIN, Ireland, June 12, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve [...]
First Medical Patent Issued for the Oculenz™ Augmented Reality Glasses
12/06/2018
Ocutrx™ AR Glasses Garners First Medical Patent for Restoring Functional Sight to Patients with Visual Field Deficits IRVINE, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- Ocutrx Vision Technologies, LLC, a California based [...]
William Demant Holding A/S: Investor news - agenda and presentations for Capital Markets Day 2018
12/06/2018
Investor news 12 June 2018 Agenda and presentations for Capital Markets Day 2018 William Demant Holding A/S will today host its Capital Markets Day 2018 in London with the following agenda: 09:30 Registration 10:00 [...]
FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares
12/06/2018
FIT Biotech Oy Company release June 12, 2018 at 10:00 AM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on December 22, 2017 [...]
Sentia Medical Sciences Inc. Appoints Dr. Yvette Taché as Chair of the Scientific Advisory Board and Announces Award of a Phase 1 Small Business Innovation Research (SBIR) Grant to Develop Astressins for the Treatment of Irritable Bowel Syndrome (IBS)
12/06/2018
SAN DIEGO, June 12, 2018 (GLOBE NEWSWIRE) -- Sentia announced today the appointment of Dr. Yvette Taché, Ph.D. as Chair of the Scientific Advisory Board. Dr. Taché, Ph.D. is a Distinguished Professor in the Vatche and [...]
Solon Eiendom ASA : Primary insider notification
12/06/2018
(Oslo, Norway, June 11, 2018) UFI AS has today bought 15.145 shares in Solon Eiendom ASA at a price of NOK 30.027 per share. Solon Eiendom ASA Board Member Øystein A. Landvik owns 33,34 % of the shares in UFI AS. [...]
Shire plc : Rule 2.9 Announcement
12/06/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 12 June 2018 Shire [...]

Pages